文献速递甲状腺核医学

重组人促甲状腺激素辅助分化型甲状腺癌患者动态评估

RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-06-09

这项在中国27个中心开展的3期开放标签自身对照试验评估了新型重组人促甲状腺激素(ZGrhTSH)替代甲状腺激素撤退(THW)用于分化型甲状腺癌(DTC)动态评估的效果。结果显示,两阶段诊断性全身扫描(Dx-WBS)一致性为88.2%(95%CI 83.7-92.7%),刺激后甲状腺球蛋白(Tg)以1 ng/mL为切点的一致性为90.4%(95%CI 86.1-94.6%),扫描联合Tg的一致性为93.6%(95%CI 90.1-97.1%)。ZGrhTSH相关不良事件见于22例患者(10.9%),均为1或2级轻度一过性事件。

要点

  • ZGrhTSH刺激与THW两阶段Dx-WBS一致性为88.2%(95%CI 83.7-92.7%)。
  • 刺激后Tg以1 ng/mL为切点时两阶段一致性为90.4%(95%CI 86.1-94.6%)。
  • 扫描联合刺激后Tg的两阶段一致性为93.6%(95%CI 90.1-97.1%)。

核心结论

  • ZGrhTSH在检测放射性碘摄取和血清Tg方面表现非劣效,可能成为DTC患者动态评估的有效且安全的替代选择。

研究设计与样本

  • 3期开放标签多中心自身对照试验,在中国27个中心开展,纳入既往行全甲状腺切除或近全甲状腺切除、伴或不伴放射性碘治疗的患者。
  • 所有参与者在ZGrhTSH刺激阶段和THW阶段均行Dx-WBS和血清Tg检测,比较两阶段Dx-WBS结果、刺激后Tg水平及其联合应用的一致性,并评估ZGrhTSH的安全性和免疫原性。
  • 试验注册号NCT04971473,注册日期2021年7月7日。

主要发现

  • 两阶段扫描一致性率为88.2%(95%CI 83.7-92.7%)。
  • 刺激后Tg以1 ng/mL为切点时,两阶段一致性率为90.4%(95%CI 86.1-94.6%)。
  • 扫描联合刺激后Tg的两阶段一致性为93.6%(95%CI 90.1-97.1%)。
  • ZGrhTSH相关不良事件报告于22例患者(10.9%),均为1或2级轻度且一过性。

关键数值与推荐

  • 刺激后Tg切点为1 ng/mL时,两阶段一致性率为90.4%(95%CI 86.1-94.6%)。

临床怎么用

  • 原文结论认为ZGrhTSH在检测放射性碘摄取和血清Tg方面表现非劣效,可能成为DTC患者动态评估的有效且安全的替代选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the efficacy of a novel recombinant human thyroid-stimulating hormone (ZGrhTSH) as an alternative to thyroid hormone withdrawal (THW) in dynamic assessment of DTC patients. METHODS: This phase 3, open-label, multicenter trial, conducted across 27 sites in China, employed a self-controlled design to enroll patients. Eligible patients had previously undergone total or near-total thyroidectomy, with or without RAI therapy. During both the ZGrhTSH-stimulated phase and the THW phase, Dx-WBS and serum Tg measurements were performed on all participants. The study focused on the concordance of Dx-WBS results, stimulated Tg levels, and their combination in patients across the two phases. Additionally, the safety and immunogenicity profiles of ZGrhTSH were assessed as well. RESULTS: In the assessment of radioiodine uptake and stimulated Tg levels, ZGrhTSH demonstrated efficacy comparable to that of THW. The concordance rate for scans between the two phases was 88.2% (95% CI: 83.7-92.7%). When setting stimulated Tg levels with a cutoff of 1 ng/mL, the concordance rate was 90.4% (95% CI: 86.1-94.6%), and the concordance of scans combined with stimulated Tg was 93.6% (95% CI: 90.1-97.1%). Adverse events associated with ZGrhTSH were reported in 22 patients (10.9%), all of which were mild and transient, graded as 1 or 2. CONCLUSION: ZGrhTSH showed non-inferior performance in detecting radioiodine uptake and serum Tg, and could be an effective and safe alternative for the dynamic evaluation of DTC patients. TRIAL REGISTRATION: ClinicalTrials.gov, NCT04971473. Registered July 7, 2021.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Lin Y, Wen Q, Fu W, et al. RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer. Eur J Nucl Med Mol Imaging. 2025. PMID: 40488858. doi:10.1007/s00259-025-07349-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。